ASX Quarterlies: Nuheara rockets 33pc, Dicker continues to grow, while these biotechs are all cashed up
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical...
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater...
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing...
CAR-T therapy is leading the race as the holy grail to cure cancer but like...
ASX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement...
At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel...
Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.